As we inch closer to a possible vaccine for COVID-19, we are finally filling in the details on how the pandemic is affecting every aspect of our patient’s lives.
Read Article
Links:
Janet Pope @Janetbirdope( View Tweet )
Janet Pope @Janetbirdope( View Tweet )
Dr. John Cush @RheumNow( View Tweet )
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Seasonal variations in symptoms -- commonly reported by patients with rheumatic diseases -- were not observed in a large cohort of patients with primary Sjogren's syndrome, French investigators found.
On a combined endpoint that reflected the three main symptoms of pain, fatigue, and
Read Article
Dr. Jack Cush reviews the highlights from the 2020 RWCS meeting in Maui, Hawaii.
Read Article
The European League Against Rheumatism (EULAR) has established an international collaborative group (EULAR SS Task Force) to develop the first EULAR evidence and consensus-based recommendations for the management of patients with Sjogens syndrome (SjS).
The Task Force included
Read Article
Dr. Jack Cush reviews the journal reports and news from RheumNow.com.
Be sure to register for RheumNow Live 3/13/2020 in Fort Worth
Rheumnow.live.
IgG4-related disease (IgG4-RD) is a relatively new disorder since 2003, and may present as a diagnostic challenge as it can cause fibroinflammatory pathology in nearly any organ.
A EULAR workgroup set out to develop and validate an international set of classification criteria for IgG4-
Read Article
Dr. Jack Cush recaps standout presentations and information from ACR 2019 held in Atlanta November 9-12, 2019.
Read ArticleA population-based claims study from Taiwan shows significantly increased incidences of depressive disorder, anxiety disorder, and sleep disorder in patients with primary Sjögren’s syndrome (pSS).
Taiwan’s National Health Insurance Research Database was the source of this retrospective
Read Article
Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019, including low-dose steroids in hand OA, ABA vs. ADA in double positive RA patients, psoriasis predictors of PsA, tildrakizumab and
Read Article
Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Here are a few of the highlights from day 1 EULAR in Madrid, including another IL-23 inhibitor, BTK inhibition, abatacept in Sjogren's syndrome, don't repeat the ANA, and drug free remission in systemic JIA.
Minority groups in the U.S. have differing rates of Sjögren's syndrome and exhibit distinct clinical patterns of the disease, a large cross-sectional study revealed.
The percentage of American Indians in a SS cohort of 610 patients was much higher than expected, at 25.3%, whereas the percentage
Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019.
1. Genovese Vagal nerve stimulator in RA
2.
Read Article
Here are a few of the highlights from day 1 EULAR in Madrid.
Read Article
